TSXV: ACB
VANCOUVER, Jan. 16, 2017 /CNW/ - Aurora Cannabis Inc.
("Aurora" or the "Company") (TSXV: ACB) (OTCQB: ACBFF)
(Frankfurt: 21P; WKN: A1C4WM) is
pleased to provide the following operational update.
Patient Registration Continues Rapid Pace
On December 21, 2016, Aurora
surpassed 12,000 active registered patients, less than 12 months
after the Company's first product sale in January, 2016, which is
believed to be the fastest rate of patient registration after
commencement of commercial operations achieved by any Licensed
Producer.
Recall of Product Purchased Wholesale
On January 13, 2017, Aurora
initiated a voluntary recall of product purchased from another
licensed producer and resold to clients. The other licensed
producer had previously initiated a precautionary voluntary product
recall, which affected a relatively small quantity of product
resold by Aurora. The recall is not anticipated to have material
financial or operational consequences for Aurora.
Aurora Sky Construction Update
Construction of the Company's new Aurora Sky production facility
at Edmonton International Airport
("EIA") is progressing smoothly and on schedule, with grade and
fill work essentially complete. More than 400 screw piles are now
installed for the grade beam, and office trailers and other
infrastructure have been completed at the site. The General
Contractor award is will be announced shortly, with Subtrade awards
following thereafter. Construction of the facility is expected to
be completed on schedule as planned for the second half of
2017.
Radient Technologies Joint Venture Research Agreement
On January 4, 2017, Aurora signed
a Joint Venture Research Agreement with Radient Technologies Inc.
("RTI"). The first phase of this venture will include screening
experiments of extraction conditions, while phase two includes
larger scale experiments related to extraction throughput and
optimal extraction conditions. Aurora's scientists and the RTI team
will commence tests January 16, 2017,
and the first phase is expected to be completed within
approximately six weeks.
Legal Update
Further to the Company's news release dated March 4, 2016, Aurora has now settled both
outstanding legal proceedings and as such, is no longer involved in
any further litigation.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises
Inc., is a licensed producer of medical cannabis pursuant to Health
Canada's Access to Cannabis for Medical Purposes Regulations
(ACMPR) and operates a 55,200 square foot, expandable,
state-of-the-art production facility in Mountain View County,
Alberta, Canada. Aurora trades on
the TSX Venture Exchange under the symbol "ACB".
On behalf of the Board of Directors,
AURORA CANNABIS INC.
Terry Booth
CEO
This news release contains certain "forward-looking
statements" within the meaning of such statements under applicable
securities law. Forward-looking statements are frequently
characterized by words such as "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed" and other similar words, or
statements that certain events or conditions "may" or "will" occur.
These statements are only predictions. Various assumptions were
used in drawing the conclusions or making the projections contained
in the forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. The Company is
under no obligation, and expressly disclaims any intention or
obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as expressly required by applicable law.
The TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Aurora Cannabis Inc.